Delays in screening, diagnosis and monitoring are associated with worse clinical and economic outcomes for patients with chronic kidney disease: a narrative review

This publication has 87 references indexed in Scilit:

• The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients
  Clinical and Experimental Nephrology, 2024
• Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes
  JAMA Network Open, 2024
• Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney Disease
  JAMA Network Open, 2023
• The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis
  International Urology and Nephrology, 2023
• Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
  JAMA Cardiology, 2021
• Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
  Advances in Therapy, 2021
• Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review
  Advances in Therapy, 2021
• The social cost of chronic kidney disease in Italy
  The European Journal of Health Economics, 2016
• Cost-effectiveness of chronic kidney disease mass screening test in Japan
  Clinical and Experimental Nephrology, 2011
• Screening for Proteinuria in US Adults
  JAMA, 2003